Up­dat­ed: Pfiz­er drops half of par­tic­i­pants from Ly­me tri­al af­ter say­ing re­search con­trac­tor broke rules

Pfiz­er is re­mov­ing about sev­er­al thou­sand US par­tic­i­pants from a Phase III Ly­me dis­ease tri­al be­cause a con­trac­tor run­ning some clin­i­cal sites vi­o­lat­ed qual­i­ty stan­dards, the drug­mak­er and its French biotech part­ner Val­ne­va said Fri­day.

Pfiz­er said that about 7,000 peo­ple had been en­rolled so far, and half will be re­moved. They’re be­ing pulled be­cause of vi­o­la­tions of Good Clin­i­cal Prac­tice (GCP) rules, which re­fer to the eth­i­cal and sci­en­tif­ic stan­dards for sites, the com­pa­nies said in a press re­lease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN